Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 5,326–5,350 of 27,380 studies, newest first · page 214 of 1096.

February 2025 25

  1. 2025-02-03

    Home as mind: AI extenders and affective ecologies in dementia care

    ✓ Peer-reviewed Caregiving Synthese

    Key finding: I consider applications of “AI extenders” to dementia care.

  2. 2025-02-03

    Extreme Heat and Hospitalization Among Older Persons With Alzheimer Disease and Related Dementias

    ✓ Peer-reviewed Risk factors JAMA Internal Medicine

    Key finding: The sample included 3 329 977 beneficiaries (2 126 290 [63.9%] female, 33 887 [1.0%] Asian, 354 771 [10.7%] Black, 61 515 [1.8%] Hispanic, 2 831 391 [85.0%] White, and 891 815 [26.8%] dual eligible for Medicaid). +4 more findings

  3. 2025-02-03

    Bioaccumulation of microplastics in decedent human brains

    ✓ Peer-reviewed Getting a diagnosis Nature medicine

    Key finding: MNPs in these organs primarily consist of polyethylene, with lesser but significant concentrations of other polymers. +3 more findings

  4. 2025-02-03

    Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease: A Randomized Clinical Trial

    ✓ Peer-reviewed Treatments JAMA network open

    Key finding: For the intention-to-treat analysis, 60 patients between ages 51 and 82 years (mean [SD], 70.65 [8.16] years; 30 females; 30 males) were included. +4 more findings

  5. 2025-02-03

    Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity

    ✓ Peer-reviewed Biomarkers JAMA network open

    Key finding: The mean (SD) baseline age of 758 participants was 61.5 (6.1) years, and 424 participants [55.9%] were female. +3 more findings

  6. 2025-02-03

    A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

    ✓ Peer-reviewed Biomarkers Brain

    Key finding: Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff < 0.007). +4 more findings

  7. 2025-02-02

    Network models of late life depression symptoms and cognitive impairments across time

    ✓ Peer-reviewed Risk factors Aging & mental health

    Key finding: Across 3544 participants, ≥65 years of age, with no diagnosed dementia-related disorders, the depression symptom everything was an effort showed high expected influence across all time points. +4 more findings

  8. 2025-02 month only

    Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p-tau217), and Amyloid Probability Score 2 were associated with 1.29 (P = 0.09), 1.38 (P < 0.001), and 1.20 (P = 0.05) increases, respectively, in the hazard of progression from A- to A+ and 0.27 (P = 0.16), 0.50 (P = 0.007), and 0.28 (P = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change. +4 more findings

  9. 2025-02 month only

    Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Models including plasma biomarkers yielded the most accurate predictions of tau-PET burden (best model: R-squared = 0.66-0.69), with especially high contribution from plasma phosphorylated tau-217 (p-tau217). +4 more findings

  10. 2025-02 month only

    Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: On NULISA, phosphorylated tau (p-tau217, p-tau231, and p-tau181), glial fibrillary acidic protein (GFAP), and microtubule-associated protein tau (MAPT-tau) showed the top significant association with amyloid beta (Aβ) positron emission tomography (PET) status, followed by the neuroinflammation markers C-C motif ligand 2 (CCL2), chitotriosidase 1 (CHIT1) and interleukin-8 (CXCL8), and the synaptic marker neurogranin (NRGN). +4 more findings

  11. 2025-02 month only

    A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. +4 more findings

  12. 2025-02-01

    Examining multimorbidity contributors to dementia over time

    ✓ Peer-reviewed Vascular contributions Alzheimer s & Dementia

    Key finding: Hypertension, acute myocardial infarction, atrial fibrillation, diabetes, heart failure, ischemic heart disease, stroke, and arthritis additively accounted for 71.8% (95% confidence interval [CI]: 62.9%-79.1%) of ADRD incident cases based on LE-AAF. +4 more findings

  13. 2025-02-01
  14. 2025-02-01

    Protocol for a meta-review of interventions to prevent and manage ICU delirium

    ✓ Peer-reviewed Clinical safety BMJ Open

    Key finding: ICU delirium is also associated with increased mortality and dementia in the longer term. +2 more findings

  15. 2025-02-01

    Impact of frailty status on the effect of a multidomain lifestyle intervention on cognition

    ✓ Peer-reviewed Prevention trials Age and Ageing

    Key finding: Frailty status (prefrail/frail n = 520, robust n = 625) at baseline did not modify the effect of intervention on global cognition during the 2-year follow-up (P-value for frailty × intervention × time interaction > .05). +4 more findings

  16. 2025-02-01
  17. 2025-02-01

    The interaction between dysfunction of vasculature and tauopathy in Alzheimer's disease and related dementias

    ✓ Peer-reviewed Disease mechanisms Alzheimer s & Dementia

    Key finding: Our findings indicate that the prevention and treatment of vascular health may be a potential target for ADRD combination therapy. +1 more finding

  18. 2025-02-01
  19. 2025-02-01

    Bidirectional relationship between epigenetic age and stroke, dementia, and late-life depression

    ✓ Peer-reviewed Brain tissue and pathology Nature Communications

    Key finding: Participants with a prior brain health event are 4% epigenetically older (β = 0.04, SE = 0.01), indicating these conditions are associated with accelerated aging beyond that captured by chronological age. +4 more findings

  20. 2025-02-01

    Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts

    ✓ Peer-reviewed Long-term cohort studies Alzheimer s & Dementia

    Key finding: After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD. +4 more findings

  21. 2025-02-01

    Perspective: Emerging challenges for a future ADNI

    ✓ Peer-reviewed Long-term cohort studies Alzheimer s & Dementia

    Key finding: In the last two decades, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has significantly advanced our understanding, technologies, and methods for detecting and diagnosing Alzheimer's disease and related dementias.

  22. 2025-02-01

    Associations of Frailty Status and Sleep Quality With Incident Delirium: A Prospective Study in the UK Biobank

    ✓ Peer-reviewed Long-term cohort studies CNS Neuroscience & Therapeutics

    Key finding: During a median follow-up of 13.8 years, 6554 (1.9%) cases of incident delirium were documented. +4 more findings

  23. 2025-02-01
  24. 2025-02-01

    Etomidate ameliorates Alzheimer-like neuropathology and cognitive impairment in APP/PS1 mice

    ✓ Peer-reviewed Risk genes beyond APOE Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

    Key finding: In conclusion, etomidate ameliorates Alzheimer-like neuropathology and cognitive impairment in APP/PS1 mice, indicating that etomidate may be a potentially useful drug for the treatment of AD.

  25. 2025-02-01

Browse the library by subject, with the full score breakdown →